NanoString

CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.

The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.

The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.

The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.

This Week in PLOS

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.

At least two early-access users, at Massachusetts General Hospital and at Weill Cornell, have explored the new platform for infectious disease testing.

The company beat Wall Street estimates, and officials said momentum is building as the firm readies its GeoMx digital spatial profiling technology for launch.

The firms have agreed to conduct joint research using NanoString's PanCancer IO 360 panel to explore predictive signatures for MacroGenics' MGD013 clinical applications.

The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.

Pages

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.